GlassScriptPhysician profile
Ronald Hauptman
NPI 1699779074
$10,749.59
in general payments reported to CMS, 2019-2025
33 companies · $2,732 in 2025
The $2,732 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $507 · 2021: $1,312 · 2022: $1,010 · 2023: $1,707 · 2024: $2,718 · 2025: $2,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,085 · Education: $72.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,084.61 |
| Education | $72.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,762.23 | 2019-2025 | |
| Gilead Sciences, INC. | $1,229.11 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $992.61 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $912.95 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $831.75 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $802.08 | 2021-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $397.11 | 2019-2025 | |
| Madrigal Pharmaceuticals | $389.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $329.94 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $276.25 | 2019-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $244.41 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $228.79 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $218.88 | 2019-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $210.92 | 2024-2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $182.54 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Lilly USA, LLC | $123.63 | 2023-2025 | Omvoh |
| Redhill Biopharma INC. | $83.64 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $54.99 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $43.98 | 2021-2023 | Linzess |
| Alfasigma USA, INC. | $42.98 | 2020 | |
| Ardelyx, INC. | $35.71 | 2022-2023 | Ibsrela |
| Evoke Pharma, INC. | $34.56 | 2024 | |
| Abbott Laboratories | $27.07 | 2024 | Proclaim |
| Fresenius Kabi USA, LLC | $26.77 | 2023 | Idacio |
| Biocon Biologics INC | $25.85 | 2025 | Yesintek |
| Ucb, INC. | $24.72 | 2019 | |
| Medtronic, INC. | $24.66 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.58 | 2019 | |
| Daiichi Sankyo INC. | $17.61 | 2019 | |
| Allergan, INC. | $16.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2023 | Cyltezo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$52,173.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hauptman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.